Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1991 Jan;54(1):51–54. doi: 10.1136/jnnp.54.1.51

Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.

T E Feasby 1
PMCID: PMC1014299  PMID: 1901348

Abstract

Three patients with acute Guillain-Barré syndrome were treated early in the course of the disease with OKT3, an anti-T-cell monoclonal antibody. Each patient developed acute lymphopenia with specific depletion of T3-positive lymphocytes. Two patients had continued progression of clinical deficits for eight and 14 days. This suggests that T lymphocytes may not be essential for progression of Guillain-Barré syndrome at this stage of the disease.

Full text

PDF
51

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asbury A. K., Arnason B. G., Adams R. D. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969 May;48(3):173–215. doi: 10.1097/00005792-196905000-00001. [DOI] [PubMed] [Google Scholar]
  2. Birchem R., Mithen F. A., L'Empereur K. M., Wessels M. M. Ultrastructural effects of Guillain-Barré serum in cultures containing only rat Schwann cells and dorsal root ganglion neurons. Brain Res. 1987 Sep 22;421(1-2):173–185. doi: 10.1016/0006-8993(87)91288-1. [DOI] [PubMed] [Google Scholar]
  3. Chatenoud L., Baudrihaye M. F., Kreis H., Goldstein G., Schindler J., Bach J. F. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol. 1982 Nov;12(11):979–982. doi: 10.1002/eji.1830121116. [DOI] [PubMed] [Google Scholar]
  4. Chatenoud L., Ferran C., Bach J. F. In-vivo anti-CD3 treatment of autoimmune patients. Lancet. 1989 Jul 15;2(8655):164–164. doi: 10.1016/s0140-6736(89)90226-2. [DOI] [PubMed] [Google Scholar]
  5. Chatenoud L., Ferran C., Reuter A., Legendre C., Gevaert Y., Kreis H., Franchimont P., Bach J. F. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med. 1989 May 25;320(21):1420–1421. doi: 10.1056/NEJM198905253202117. [DOI] [PubMed] [Google Scholar]
  6. Cornblath D. R., McArthur J. C., Kennedy P. G., Witte A. S., Griffin J. W. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol. 1987 Jan;21(1):32–40. doi: 10.1002/ana.410210107. [DOI] [PubMed] [Google Scholar]
  7. Drachman D. A., Paterson P. Y., Berlin B. S., Roguska J. Immunosuppression and the Guillain-Barré syndrome. Arch Neurol. 1970 Nov;23(5):385–393. doi: 10.1001/archneur.1970.00480290005001. [DOI] [PubMed] [Google Scholar]
  8. Emmons C., Smith J., Flanigan M. Cerebrospinal fluid inflammation during OKT3 therapy. Lancet. 1986 Aug 30;2(8505):510–511. doi: 10.1016/s0140-6736(86)90375-2. [DOI] [PubMed] [Google Scholar]
  9. Feasby T. E., Hahn A. F., Gilbert J. J. Passive transfer studies in Guillain-Barré polyneuropathy. Neurology. 1982 Oct;32(10):1159–1167. doi: 10.1212/wnl.32.10.1151-a. [DOI] [PubMed] [Google Scholar]
  10. Fung J. J., Markus B. H., Gordon R. D., Esquivel C. O., Makowka L., Tzakis A., Starzl T. E. Impact of Orthoclone OKT3 on liver transplantation. Transplant Proc. 1987 Apr;19(2 Suppl 1):37–44. [PMC free article] [PubMed] [Google Scholar]
  11. Hartung H. P., Hughes R. A., Taylor W. A., Heininger K., Reiners K., Toyka K. V. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology. 1990 Feb;40(2):215–218. doi: 10.1212/wnl.40.2.215. [DOI] [PubMed] [Google Scholar]
  12. Koski C. L., Gratz E., Sutherland J., Mayer R. F. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome. Ann Neurol. 1986 Jun;19(6):573–577. doi: 10.1002/ana.410190609. [DOI] [PubMed] [Google Scholar]
  13. Lisak R. P., Mitchell M., Zweiman B., Orrechio E., Asbury A. K. Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies. Ann Neurol. 1977 Jan;1(1):72–78. doi: 10.1002/ana.410010107. [DOI] [PubMed] [Google Scholar]
  14. Strigård K., Olsson T., Larsson P., Holmdahl R., Klareskog L. Modulation of experimental allergic neuritis in rats by in vivo treatment with monoclonal anti T cell antibodies. J Neurol Sci. 1988 Feb;83(2-3):283–291. doi: 10.1016/0022-510x(88)90075-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES